我国医疗机构重点监控药品监测平台合理应用管理指标的探讨
x

请在关注微信后,向客服人员索取文件

篇名: 我国医疗机构重点监控药品监测平台合理应用管理指标的探讨
TITLE: Discussion on the Monitoring Platform of Rational Use Management Indexes of Key Monitored Drugs of Medical Institutions in China
摘要: 目的:探讨重点监控药品监测平台的合理应用管理指标,为提高重点监控药品临床应用管理水平提供参考。方法:采用文献研究和专家论证的方法,提出医疗机构重点监控药品的指标。结果与结论:最终明确了医疗机构采购前20位药品目录、重点监控药品采购品规数、住院患者重点监控药品使用率、重点监控药品收入占比、住院患者重点监控药品费用增幅、住院患者单个重点监控药品费用增幅、住院患者重点监控药品次均费用增幅、使用重点监控药品的医嘱点评比例等8项重点监控药品通用性指标,以及医疗机构基本情况、病案首页、住院患者用药数据、医疗机构药品采购数据等4项数据采集项目。综上,建立的医疗机构重点监控药品监测平台可为提高重点监控药品临床应用管理提供参考。
ABSTRACT: OBJECTIVE:To d iscuss the monitoring platform of rational use management indexes of key monitored drugs ,and to provide reference for improving their clinical application management. METHODS :The method of literature research and expert demonstration was adopted ,the indexes of key monitored drugs in medical institutions were put forward. RESULTS & CONCLUSIONS:Finally,Eight general indexes as the list of top 20 drugs purchased by medical institutions ,the specifications of key monitored drugs purchased ,the utilization rate of key monitored drugs of inpatient ,the proportion of key monitored drugs revenue,the increase in the cost of key monitored drugs of inpatient ,the increase in the cost of key monitored drug of single inpatient,the increase of the cost per time of key monitored drugs of inpatient ,the proportion of doctor ’s order review for key monitored drugs were defined. Four major data acquisition projects as the general information of medical institutions ,medical record homepage ,inpatient medication data ,and medical institution drug procurement data were also defined. The monitoring platform of key monitored drugs in medical institutions can provide reference for improving the management of clinical application of key monitored drugs.
期刊: 2021年第32卷第08期
作者: 王笛,王相峰,毛丽超,熊伟,赵靖
AUTHORS: WANG Di,WANG Xiangfeng,MAO Lichao,XIONG Wei,ZHAO Jing
关键字: 重点监控药品;监测平台;数据采集;合理用药
KEYWORDS: Key monitored dr ugs;Monitoring p latform;Data acquisition ;Rational drug u se
阅读数: 368 次
本月下载数: 12 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!